KRAS and mesothelioma: Importantly, we observed no significant differences in pyrimidine metabolism between patients with NF2 deficiencies who had KRAS mutations and those with wild-type KRAS. This aligns with our finding that KRAS knockdown does not affect the NF2-driven increase in CAD and DHODH expression, suggesting the alterations in pyrimidine metabolism associated with NF2 deficiency occur independently of KRAS signaling in mesothelioma (Appendix Fig. S6).